Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.17
ABBV's Cash-to-Debt is ranked lower than
87% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. ABBV: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
ABBV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.59 Max: No Debt
Current: 0.17
Equity-to-Asset 0.08
ABBV's Equity-to-Asset is ranked lower than
97% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ABBV: 0.08 )
Ranked among companies with meaningful Equity-to-Asset only.
ABBV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.11 Max: 0.69
Current: 0.08
-0.01
0.69
Interest Coverage 8.62
ABBV's Interest Coverage is ranked lower than
75% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. ABBV: 8.62 )
Ranked among companies with meaningful Interest Coverage only.
ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 37.44 Max: No Debt
Current: 8.62
Piotroski F-Score: 6
Altman Z-Score: 2.26
Beneish M-Score: -2.42
WACC vs ROIC
8.91%
21.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 36.33
ABBV's Operating Margin % is ranked higher than
96% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. ABBV: 36.33 )
Ranked among companies with meaningful Operating Margin % only.
ABBV' s Operating Margin % Range Over the Past 10 Years
Min: 17.09  Med: 30.91 Max: 36.6
Current: 36.33
17.09
36.6
Net Margin % 24.07
ABBV's Net Margin % is ranked higher than
91% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. ABBV: 24.07 )
Ranked among companies with meaningful Net Margin % only.
ABBV' s Net Margin % Range Over the Past 10 Years
Min: 8.89  Med: 22.86 Max: 32.62
Current: 24.07
8.89
32.62
ROE % 119.29
ABBV's ROE % is ranked higher than
99% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. ABBV: 119.29 )
Ranked among companies with meaningful ROE % only.
ABBV' s ROE % Range Over the Past 10 Years
Min: 24.85  Med: 91.09 Max: 199.32
Current: 119.29
24.85
199.32
ROA % 9.88
ABBV's ROA % is ranked higher than
77% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. ABBV: 9.88 )
Ranked among companies with meaningful ROA % only.
ABBV' s ROA % Range Over the Past 10 Years
Min: 6.25  Med: 14.69 Max: 39.54
Current: 9.88
6.25
39.54
ROC (Joel Greenblatt) % 323.60
ABBV's ROC (Joel Greenblatt) % is ranked higher than
98% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. ABBV: 323.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABBV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 75.1  Med: 146.37 Max: 323.6
Current: 323.6
75.1
323.6
3-Year Revenue Growth Rate 10.30
ABBV's 3-Year Revenue Growth Rate is ranked higher than
68% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. ABBV: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABBV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.7 Max: 10.3
Current: 10.3
0
10.3
3-Year EBITDA Growth Rate 15.10
ABBV's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. ABBV: 15.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABBV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 15.1
Current: 15.1
0
15.1
3-Year EPS without NRI Growth Rate 12.30
ABBV's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. ABBV: 12.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABBV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.2 Max: 12.3
Current: 12.3
0
12.3
GuruFocus has detected 4 Warning Signs with AbbVie Inc $ABBV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABBV's 30-Y Financials

Financials (Next Earnings Date: 2017-10-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Tom Russo 17,106 sh (unchged)
Stanley Druckenmiller 1,324,920 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Eaton Vance Worldwide Health Sciences Fund 742,955 sh (-39.35%)
» More
Q4 2016

ABBV Guru Trades in Q4 2016

Richard Pzena 3,476 sh (New)
Steven Cohen 1,136,566 sh (New)
David Dreman 22,908 sh (+52.53%)
Larry Robbins 9,116,969 sh (+51.19%)
Joel Greenblatt 935,437 sh (+36.69%)
Scott Black 37,816 sh (+2.91%)
Lee Ainslie 50,920 sh (+2.66%)
Manning & Napier Advisors, Inc 160,726 sh (+2.02%)
Ken Fisher 696,569 sh (+1.83%)
Jeff Auxier 20,825 sh (+0.98%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Tom Russo 17,106 sh (unchged)
NWQ Managers Sold Out
Mario Gabelli 20,076 sh (-0.59%)
Mairs and Power 264,365 sh (-0.78%)
Murray Stahl 33,854 sh (-3.43%)
PRIMECAP Management 901,845 sh (-5.45%)
Stanley Druckenmiller 1,221,723 sh (-7.79%)
Paul Tudor Jones 4,900 sh (-44.94%)
Jim Simons 350,800 sh (-81.71%)
Pioneer Investments 112,829 sh (-90.02%)
Eaton Vance Worldwide Health Sciences Fund 690,536 sh (-7.06%)
» More
Q1 2017

ABBV Guru Trades in Q1 2017

Leucadia National 8,008 sh (New)
NWQ Managers 4,234 sh (New)
Jeremy Grantham 5,500 sh (New)
Caxton Associates 7,100 sh (New)
Jim Simons 2,087,956 sh (+495.20%)
Paul Tudor Jones 12,162 sh (+148.20%)
Richard Pzena 4,170 sh (+19.97%)
Jeff Auxier 22,825 sh (+9.60%)
Scott Black 40,867 sh (+8.07%)
Manning & Napier Advisors, Inc 168,153 sh (+4.62%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jana Partners 100,000 sh (unchged)
Stanley Druckenmiller Sold Out
Pioneer Investments Sold Out
Murray Stahl 33,453 sh (-1.18%)
Ken Fisher 682,915 sh (-1.96%)
David Dreman 22,356 sh (-2.41%)
Mairs and Power 256,342 sh (-3.03%)
Mario Gabelli 19,376 sh (-3.49%)
Tom Russo 16,200 sh (-5.30%)
PRIMECAP Management 826,345 sh (-8.37%)
Lee Ainslie 44,400 sh (-12.80%)
Steven Cohen 940,300 sh (-17.27%)
Larry Robbins 7,301,967 sh (-19.91%)
Joel Greenblatt 618,480 sh (-33.88%)
Eaton Vance Worldwide Health Sciences Fund 187,548 sh (-72.84%)
» More
Q2 2017

ABBV Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 258,056 sh (+53.46%)
Ken Fisher 686,519 sh (+0.53%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 5122
Compare:NYSE:LLY, NYSE:BMY, NYSE:MRK, NYSE:PFE, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, AMEX:NNVC, NAS:ALIM, NAS:PRPH, NAS:TNXP, NAS:IMNP, AMEX:AXN, OTCPK:INNV, NAS:ALQA, OTCPK:INBP, OTCPK:ECTE, OTCPK:ENZB » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
Headquarter Location:USA
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the firm's current profits. The company was spun off from Abbott in early 2013.

Top Ranked Articles about AbbVie Inc

AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis
Billionaires Bet Big On Canada's Newest $22 Billion Market
AbbVie to Host Second-Quarter 2017 Earnings Conference Call
AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
AbbVie Declares Quarterly Dividend
AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors
AbbVie Presents Results of 2 Studies on Imbruvica Drug was shown to aid patients' survival and better target cancer cells
AbbVie Inc. (NYSE:ABBV) presented the results of two studies in which the researchers tested Imbruvica (ibrutinib) on lymphoblastic leukemia patients at the American Society of Clinical Oncology’s (ASCO) 53rd Annual Meeting in Chicago on June 5. Read more...
AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis
Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Dise
New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients

Ratios

vs
industry
vs
history
PE Ratio 19.15
ABBV's PE Ratio is ranked higher than
71% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. ABBV: 19.15 )
Ranked among companies with meaningful PE Ratio only.
ABBV' s PE Ratio Range Over the Past 10 Years
Min: 9.85  Med: 18.56 Max: 63.37
Current: 19.15
9.85
63.37
Forward PE Ratio 13.23
ABBV's Forward PE Ratio is ranked higher than
76% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. ABBV: 13.23 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.15
ABBV's PE Ratio without NRI is ranked higher than
71% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. ABBV: 19.15 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABBV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.85  Med: 18.56 Max: 63.37
Current: 19.15
9.85
63.37
Price-to-Owner-Earnings 22.40
ABBV's Price-to-Owner-Earnings is ranked higher than
67% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. ABBV: 22.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABBV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.74  Med: 19.34 Max: 61.16
Current: 22.4
13.74
61.16
PB Ratio 23.57
ABBV's PB Ratio is ranked lower than
98% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. ABBV: 23.57 )
Ranked among companies with meaningful PB Ratio only.
ABBV' s PB Ratio Range Over the Past 10 Years
Min: 14.08  Med: 20.51 Max: 76.98
Current: 23.57
14.08
76.98
PS Ratio 4.58
ABBV's PS Ratio is ranked lower than
64% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. ABBV: 4.58 )
Ranked among companies with meaningful PS Ratio only.
ABBV' s PS Ratio Range Over the Past 10 Years
Min: 2.83  Med: 4.19 Max: 5.68
Current: 4.58
2.83
5.68
Price-to-Free-Cash-Flow 18.28
ABBV's Price-to-Free-Cash-Flow is ranked higher than
64% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. ABBV: 18.28 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABBV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.66  Med: 15.16 Max: 38.16
Current: 18.28
8.66
38.16
Price-to-Operating-Cash-Flow 17.10
ABBV's Price-to-Operating-Cash-Flow is ranked higher than
55% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. ABBV: 17.10 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABBV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.2  Med: 14.04 Max: 31.59
Current: 17.1
8.2
31.59
EV-to-EBIT 15.95
ABBV's EV-to-EBIT is ranked higher than
65% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. ABBV: 15.95 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.5 Max: 42.5
Current: 15.95
10.2
42.5
EV-to-EBITDA 14.00
ABBV's EV-to-EBITDA is ranked higher than
62% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. ABBV: 14.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.6 Max: 34.1
Current: 14
8.6
34.1
PEG Ratio 2.01
ABBV's PEG Ratio is ranked lower than
51% of the 313 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. ABBV: 2.01 )
Ranked among companies with meaningful PEG Ratio only.
ABBV' s PEG Ratio Range Over the Past 10 Years
Min: 2.01  Med: 2.27 Max: 2.75
Current: 2.01
2.01
2.75
Current Ratio 1.76
ABBV's Current Ratio is ranked lower than
65% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ABBV: 1.76 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.8 Max: 2.82
Current: 1.76
1.22
2.82
Quick Ratio 1.60
ABBV's Quick Ratio is ranked lower than
55% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. ABBV: 1.60 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.62 Max: 2.65
Current: 1.6
1.06
2.65
Days Inventory 96.60
ABBV's Days Inventory is ranked higher than
62% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. ABBV: 96.60 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 89.28 Max: 115.3
Current: 96.6
35.55
115.3
Days Sales Outstanding 65.11
ABBV's Days Sales Outstanding is ranked higher than
58% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. ABBV: 65.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.11  Med: 78.73 Max: 93.3
Current: 65.11
65.11
93.3
Days Payable 84.47
ABBV's Days Payable is ranked higher than
60% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. ABBV: 84.47 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 129.53 Max: 185.97
Current: 84.47
30.33
185.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.37
ABBV's Dividend Yield % is ranked higher than
82% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. ABBV: 3.37 )
Ranked among companies with meaningful Dividend Yield % only.
ABBV' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 3.11 Max: 3.96
Current: 3.37
0.85
3.96
Dividend Payout Ratio 0.61
ABBV's Dividend Payout Ratio is ranked lower than
68% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. ABBV: 0.61 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABBV' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.64 Max: 1.51
Current: 0.61
0.61
1.51
3-Year Dividend Growth Rate 12.50
ABBV's 3-Year Dividend Growth Rate is ranked higher than
65% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. ABBV: 12.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABBV' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.5
Current: 12.5
0
12.5
Forward Dividend Yield % 3.43
ABBV's Forward Dividend Yield % is ranked higher than
85% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABBV: 3.43 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.37
ABBV's 5-Year Yield-on-Cost % is ranked higher than
67% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. ABBV: 3.37 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABBV' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.85  Med: 3.1 Max: 3.96
Current: 3.37
0.85
3.96
3-Year Average Share Buyback Ratio -0.80
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. ABBV: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.3 Max: 0
Current: -0.8
-0.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.84
ABBV's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. ABBV: 1.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABBV' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.62  Med: 1.72 Max: 1.86
Current: 1.84
1.62
1.86
Price-to-Median-PS-Value 1.09
ABBV's Price-to-Median-PS-Value is ranked higher than
51% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. ABBV: 1.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABBV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 0.98 Max: 1.26
Current: 1.09
0.7
1.26
Price-to-Peter-Lynch-Fair-Value 2.46
ABBV's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 207 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. ABBV: 2.46 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABBV' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.11  Med: 2.26 Max: 2.7
Current: 2.46
2.11
2.7
Earnings Yield (Greenblatt) % 6.27
ABBV's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ABBV: 6.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABBV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 6.45 Max: 9.8
Current: 6.27
2.4
9.8
Forward Rate of Return (Yacktman) % 12.62
ABBV's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. ABBV: 12.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABBV' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 13.1 Max: 14.4
Current: 12.62
11.8
14.4

More Statistics

Revenue (TTM) (Mil) $26,218.00
EPS (TTM) $ 3.86
Beta1.43
Short Percentage of Float1.72%
52-Week Range $55.06 - 75.04
Shares Outstanding (Mil)1,591.54

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27,731 30,375 32,358
EPS ($) 5.54 6.61 7.61
EPS without NRI ($) 5.54 6.61 7.61
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.93%
Dividends per Share ($) 2.58 2.76 2.86
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patie Jul 21 2017 
Billionaires Bet Big On Canada's Newest $22 Billion Market Jul 17 2017 
AbbVie to Host Second-Quarter 2017 Earnings Conference Call Jul 10 2017 
AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Jun 23 2017 
AbbVie Declares Quarterly Dividend Jun 22 2017 
AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors Jun 13 2017 
AbbVie Presents Results of 2 Studies on Imbruvica Jun 07 2017 
AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Jun 07 2017 
Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rate Jun 05 2017 
New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Jun 05 2017 

More From Other Websites
[$$] AbbVie Ordered to Pay $150 Million in AndroGel Lawsuit Jul 24 2017
U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict Jul 24 2017
Why Reata Pharmaceuticals Is Rallying 17.5% Today Jul 24 2017
AbbVie Ordered to Pay $150 Million Damages in ‘Low-T’ Trial Jul 24 2017
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs Jul 24 2017
Better Buy: Johnson & Johnson vs. AbbVie Jul 24 2017
3 Stocks That Are Absurdly Cheap Right Now Jul 23 2017
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet Jul 23 2017
Better Buy: AbbVie Inc. vs. Johnson & Johnson Jul 22 2017
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store? Jul 21 2017
AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric... Jul 21 2017
How AbbVie Could Hammer Gilead's Hepatitis C Franchise Jul 19 2017
Gilead Sciences: Not a Game Changer Jul 19 2017
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval Jul 19 2017
Cramer's charts reveal that technology isn't the only sec... Jul 18 2017
Cramer's charts reveal that technology isn't the only sector driving the rally Jul 18 2017
Perrigo Company Gets FDA Approval for Generic Topical Gel Jul 18 2017
This Drug Bellwether's Sales Miss Actually Bodes Well For The Sector Jul 18 2017
5 Big Pharma Stocks With the Best Drug Pipelines Jul 18 2017
'Stars Align' For These Biotechs To Crush Earnings Consensus Jul 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}